This study suggests that hypnotherapy is a highly effective treatment approach in an Asian population with refractory irritable bowel syndrome. Hypnotherapy significantly improves gastrointestinal, extra-intestinal, psychological symptoms, and quality of life. These data have highlighted the need for developing hypnotherapy services and population-specific clinical studies to confirm these findings in Asian countries.

The milk fat globule membrane (MFGM) has been recognized as a milk component for more than 60 years, but its exact benefits remain unknown. Research on human MFGM has revealed that the membrane holds a host of bioactive components with potential benefits for the brain–immune–gut axis in early life. Evidence indicates the potential benefits of MFGM in early life supplementation, including better cognitive development, reduction of infection risks, and modulation of the gut microbiome.

• The relationship between the characteristics of HCC diagnosed after SVR with DAA therapy and surveillance status has not been sufficiently investigated.
• This study investigated the clinical risk factors for HCC development and HCC characteristics according to which type of physician performed follow-up after SVR in Japan.
• Follow-up physician type (non-specialist) (HR, 39.100) was independently associated with HCC stage progression.

Through quality improvement (QI) methodology, we could shorten the time spent in the biologics infusion center using the accelerated infusion protocol. The project maintains patient safety. Estimated cost savings from the QI project are substantial.

We compared the effect of sarcopenia on the prognosis of unresectable-hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab and lenvatinib. In patients treated with lenvatinib, sarcopenia was the significant prognostic factor, whereas in patients treated with atezolizumab plus bevacizumab, sarcopenia does not determine prognosis.

To validate the utility of the general evaluation score (GES) for predicting the development of hepatocellular carcinoma (HCC) in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 who have received direct-acting antiviral. The incidence of HCC differed significantly by GES-based risk groups in this patient population. GES had higher predictive power for HCC development than FIB-4 index according to time-dependent receiver operating characteristic analysis.

A cohort of 497 patients with chronic hepatitis C (97% in Child–Pugh (CTP) class A and 53% with fibrosis grades 0–2) who achieved sustained virological response after direct antiviral therapy were followed for at least 24 months; albumin-bilirubin (ALBI) score improved significantly over time, including patients with ALBI grade 1 or CTP A5 at baseline. A significant improvement in ALBI was also observed across stages of fibrosis at baseline.

This is a single-arm, open-label pilot study. Oral semaglutide treatment for 24 weeks in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes improved impaired liver function, hypertriglyceridemia, insulin resistance, and hepatic steatosis, as well as improving diabetic status and reducing body weight.

An elderly frail lady with features of malnutrition was investigated by endoscopy because of nausea and vomiting. Candida esophagitis was found, and there was symptomatic and endoscopic resolution after treatment with amphotericin B.